Hormone Receptor-positive Breast Cancer Clinical Trials in Nashville, Tennessee

4 studies are recruiting for hormone receptor-positive breast cancer in Nashville, Tennessee right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

    This is a dose escalation and dose expansion study to compare how well BGB-43395, a selective cyclin-dependent kinase 4 (CDK4) inhibitor, works as monotherapy or in combination with fulvestrant, letrozole, or elacestrant in participants with hormone receptor positive (HR+) and human epidermal growt…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Scri Oncology Partners, Nashville, Tennessee
    Locations
    62 in total
    Run by
    BeOne Medicines

    See if you can join NCT06120283 on ClinicalTrials.gov

  2. ETHAN - ET for Male BC

    This research study is looking to see how well male breast cancer responds to preoperative treatment with endocrine therapy and which endocrine therapy regimen is the most effective treatment for male breast cancer. The drugs used in this study are: * Tamoxifen * Anastrozole * Degarelix * Abemacicl…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Vanderbilt Cancer Center, Nashville, Tennessee
    Locations
    9 in total
    Run by
    Jose Pablo Leone

    See if you can join NCT05501704 on ClinicalTrials.gov

  3. Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

    The aim of this study is to identify the optimal dose for EP0062 as monotherapy and in combination with standard-of-care therapies to assess its Safety, Tolerability, Pharmacokinetics, and Efficacy in Patients with Relapsed Locally Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Sarah Cannon Research Institute, Nashville, Tennessee
    Locations
    14 in total
    Run by
    Ellipses Pharma

    See if you can join NCT05573126 on ClinicalTrials.gov

  4. Study of XB010 in Subjects With Solid Tumors

    This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with locally advanced or metastatic solid tumors for whom alternative therapies do not exist or available …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    SCRI Oncology Partners, Nashville, Tennessee
    Locations
    20 in total
    Run by
    Exelixis

    See if you can join NCT06545331 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.